Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

NCT ID: NCT00413218

Last Updated: 2024-12-10

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-08

Study Completion Date

2015-03-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Candida infections, representing approximately 80% of all major systemic fungal infections, are the fourth most common cause of nosocomial bloodstream infections, with a mortality rate of 40%. Isavuconazole is not yet approved for the treatment of fungal infections. This study investigates the efficacy and safety of intravenous and oral isavuconazole. Patients are randomized to isavuconazole and the reference regimen. Patients with a positive blood- or deep tissue culture of candida fungi can be included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Candidiasis, Invasive Candidemia Mycoses

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Invasive Candida infections BAL8557 ASP9766 Isavuconazole Candidemia Candidemia and other invasive candida infections Phase III study

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Isavuconazole (ISA)

Participants received 3 intravenous (IV) loading doses of 200 mg of isavuconazole on days 1 and 2, followed by an IV maintenance dose of 200 mg once daily from day 3 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV to oral therapy. Oral therapy consisted of 200 mg isavuconazole twice daily.

Group Type EXPERIMENTAL

Isavuconazole

Intervention Type DRUG

Administered by intravenous infusion.

Caspofungin (CAS)/Voriconazole

Participants received 1 intravenous (IV) loading dose of 70 mg CAS on day 1, followed by an IV maintenance dose of 50 mg CAS from day 2 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV CAS to oral voriconazole comprising of a loading dose of 400 mg twice daily (BID) on the first day of oral therapy followed by standard dosing of 200 mg BID thereafter.

Group Type ACTIVE_COMPARATOR

Caspofungin

Intervention Type DRUG

Administered by intravenous infusion.

Voriconazole

Intervention Type DRUG

Administered by intravenous infusion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isavuconazole

Administered by intravenous infusion.

Intervention Type DRUG

Caspofungin

Administered by intravenous infusion.

Intervention Type DRUG

Voriconazole

Administered by intravenous infusion.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ASP9766 BAL8557 Cancidas VFend

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with candidemia or with an invasive Candida infection
* Presence of fever, hypothermia or other appropriate local sign of infection
* Female patients must be non-lactating and at no risk of pregnancy

Exclusion Criteria

* Patients with a sole diagnosis of mucocutaneous candidiasis, i.e. oropharyngeal, esophageal or genital candidiasis; or candidal lower urinary tract infection or Candida isolated solely from respiratory tract specimens
* Patients with candidemia who failed a previous antifungal therapy for the same infection
* Patients previously enrolled in a phase III study with isavuconazole
* Patients with a body weight \<40kg
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Basilea Pharmaceutica

INDUSTRY

Sponsor Role collaborator

Astellas Pharma Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Global Development

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Somero Research Corporation

Palm Desert, California, United States

Site Status

University of California Davis Health System

Sacramento, California, United States

Site Status

University of California at San Francisco

San Francisco, California, United States

Site Status

Idaho Falls Infectious Diseases PLLC

Idaho Falls, Idaho, United States

Site Status

Loyola University Hospital

Maywood, Illinois, United States

Site Status

Springfield Clinic LLP

Springfield, Illinois, United States

Site Status

Infectious Disease of Indiana

Indianapolis, Indiana, United States

Site Status

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Site Status

University of Maryland School of Medicine

Baltimore, Maryland, United States

Site Status

UMASS Memorial Medical Center

Worcester, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Mercury Street Medical Group

Butte, Montana, United States

Site Status

Jersey Shore University Medical Center

Neptune City, New Jersey, United States

Site Status

New York Presbyterian Hospital

New York, New York, United States

Site Status

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Site Status

Regional Infection Diseases Infusion Center Inc.

Lima, Ohio, United States

Site Status

Temple University Health Sciences

Philadelphia, Pennsylvania, United States

Site Status

Hospital Britanico de Buenos Aires

Capital Federal, , Argentina

Site Status

Hospital General de Agudos Dr. Carlos G. Durand

Capital Federal, , Argentina

Site Status

Hospital Italiano de Buenos Aires

Ciudad Autonoma, , Argentina

Site Status

Instituto Medico Especializado Alexander Fleming

Ciudad Autonoma, , Argentina

Site Status

Hospital General de Agudos Dr. Cosme Argerich

La Boca, , Argentina

Site Status

Fremantle Hospital

Fremantle, , Australia

Site Status

Mater Adult Hospital

South Brisbane, , Australia

Site Status

Westmead Hospital

Westmead, , Australia

Site Status

Princess Alexandra Hospital

Woolloongabba, , Australia

Site Status

Institut Jules Bordet

Brussels, , Belgium

Site Status

ULB Hôpital Erasme

Brussels, , Belgium

Site Status

Universitair Ziekenhuis Brussel

Brussels, , Belgium

Site Status

Universitair Ziekenhuis Gent

Ghent, , Belgium

Site Status

Universitaire Ziekenhuizen Leuven

Leuven, , Belgium

Site Status

Hospital Felicio Rocho

Belo Horizonte, , Brazil

Site Status

Hospital das Clinicas da Universidade Federal de Minas Gerai

Belo Horizonte, , Brazil

Site Status

Santa Casa de Misericordia de Belo Horizonte

Belo Horizonte, , Brazil

Site Status

Hospital das Clinicas da UFPR

Curitiba, , Brazil

Site Status

Hospital Nossa Senhora das Gracas

Curitiba, , Brazil

Site Status

Hospital Sao Lucas - PUCRS

Porto Alegre, , Brazil

Site Status

Irmandade da Santa Casa de Misericordia de Porto Alegre

Porto Alegre, , Brazil

Site Status

Hospital Universitario Clementino Fraga Filho

Rio de Janeiro, , Brazil

Site Status

Hospital Universitario de Santa Maria

Santa Maria, , Brazil

Site Status

Universidade Federal de Sao Paulo - UNIFESP

São Paulo, , Brazil

Site Status

University of Alberta Hospital

Edmonton, Alberta, Canada

Site Status

Hamilton Health Sciences - Henderson Site

Hamilton, Ontario, Canada

Site Status

Queen's University

Kingston, Ontario, Canada

Site Status

The Ottawa Hospital - General Campus

Ottawa, Ontario, Canada

Site Status

University Health Network - Toronto General Hospital

Toronto, Ontario, Canada

Site Status

Hôpital Maisonneuve - Rosemont

Montreal, Quebec, Canada

Site Status

Hospital Dr. Sotero del Rio

Puente Alto Santiago, , Chile

Site Status

Hospital del Salvador

Santiago, , Chile

Site Status

Hospital Dr. Hernan Henriquez Aravena

Temuco, , Chile

Site Status

West China Hospital of Sichuan University

Chengdu, , China

Site Status

Huashan Hospital Fudan University

Shanghai, , China

Site Status

Hôpital Hautepierre

Strasbourg, , France

Site Status

Hôpital de Brabois Adultes

Vandœuvre-lès-Nancy, , France

Site Status

Charite Campus Mitte

Berlin, , Germany

Site Status

Universitaet Koeln

Cologne, , Germany

Site Status

Universitaetsklinikum Freiburg

Freiburg im Breisgau, , Germany

Site Status

Klinikum St. Georg

Leipzig, , Germany

Site Status

Universitaetsklinik Leipzig

Leipzig, , Germany

Site Status

Universitaetsklinikum Leipzig

Lübeck, , Germany

Site Status

Universitaetsklinikum Wuerzburg

Würzburg, , Germany

Site Status

Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum

Debrecen, , Hungary

Site Status

Petz Aladar Megyei Oktato Korhaz

Győr, , Hungary

Site Status

Kasturba Medical College and Hospital

Mangalore, Karna, India

Site Status

Kasturba Medical College K. M. C. Hospital

Manipal, Karna, India

Site Status

Amrita Institute Of Medical Science

Kochi, Kerala, India

Site Status

Deenanath Mangeshkar Hospital and Research Centre

Pune, Mahara, India

Site Status

Max Super Speciality Hospital

New Delhi, National Capital Territory of Delhi, India

Site Status

Metro Centre for Respiratory Diseases

Noida, National Capital Territory of Delhi, India

Site Status

Apollo Hospitals Educational & Research Foundation

Chennai, , India

Site Status

Nizam's Institute of Medical Sciences

Hyderabad, , India

Site Status

AMRI Hospital

Kolkata, , India

Site Status

Christian Medical College & Hospital

Vellore Tamilnadu, , India

Site Status

Ha Emek Medical Center

Afula, , Israel

Site Status

Rambam Health Care Campus

Haifa, , Israel

Site Status

Wolfson Medical Center

Holon, , Israel

Site Status

Hadassah Universtiy Hospital - Ein Kerem

Jerusalem, , Israel

Site Status

Sapir Medical Center, Meir Hospital

Kfar Saba, , Israel

Site Status

Rabin MC

Petah, , Israel

Site Status

Chaim Sheba Medical Center

Ramat Gan, , Israel

Site Status

Sourasky MC Ichilov Hospital Tel Aviv

Tel Aviv, , Israel

Site Status

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Ma

Bologna, , Italy

Site Status

Azienda Ospedaliera Spedali Civili di Brescia

Brescia, , Italy

Site Status

Ente Ospedaliero Ospedeli Galliera

Genova, , Italy

Site Status

Azienda Ospedaliero Universitaria San Martino

Genova, , Italy

Site Status

Azienda Ospedaliera di Verona-Ospedale Civile Maggiore

Verona, , Italy

Site Status

AUB Medical Center

Beirut, , Lebanon

Site Status

Rafik Hariri Uni Hospital

Beirut, , Lebanon

Site Status

Hospital Ampang

Ampang, , Malaysia

Site Status

Pusat Perubatan Universiti Kebangsaan Malaysia

Kuala Lumpur, , Malaysia

Site Status

Hospital Civil de Guadalajara Fray Antonio Alcalde

Guadalajara, , Mexico

Site Status

Hospital Civil de Guadalajara Dr Juan I Menchaca

Guadalajara, , Mexico

Site Status

Instituto Nacional de Ciencias Medicas y Nutricion Salvador

México, , Mexico

Site Status

Hospital Universitario Dr Jose Eleuterio Gonzalez

Monterrey, , Mexico

Site Status

Auckland City Hospital

Auckland, , New Zealand

Site Status

Waikato Urology Research Ltd

Hamilton, , New Zealand

Site Status

De La Salle Health Sciences Institute- DLSUMC

Cavite City, , Philippines

Site Status

Philippine General Hospital

Manila, , Philippines

Site Status

S.I. Russian Oncological Research Center n.a. N.N. Blokhin

Moscow, , Russia

Site Status

State Institution "Hematology Research Center" RAMS

Moscow, , Russia

Site Status

Singapore General Hospital - Parent

Singapore, , Singapore

Site Status

National Neuroscience Institute

Singapore, , Singapore

Site Status

Unitas Hospital

Lyttelton Centurion, , South Africa

Site Status

Hospital del Mar

Barcelona, , Spain

Site Status

Hôpitaux Universitaires de Genève - HUG

Geneva, , Switzerland

Site Status

Universitaetsspital Zuerich

Zurich, , Switzerland

Site Status

Siriraj Hospital

Bangkoknoi, , Thailand

Site Status

Songklanagarind Hospital

Hat Yai, , Thailand

Site Status

Maharat Nakhon Ratchasima Hospital

Muang, , Thailand

Site Status

Srinagarind Hospital

Muang, , Thailand

Site Status

Maharaj Nakorn Chiang Mai Hospital

Muang, , Thailand

Site Status

Ramathibodi Hospital

Ratchathewi, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Colombia Egypt Netherlands Poland South Korea Turkey (Türkiye) United Kingdom United States Argentina Australia Belgium Brazil Canada Chile China France Germany Hungary India Israel Italy Lebanon Malaysia Mexico New Zealand Philippines Russia Singapore South Africa Spain Switzerland Thailand

References

Explore related publications, articles, or registry entries linked to this study.

Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, Sobel JD, Herbrecht R, Rahav G, Jaruratanasirikul S, Chetchotisakd P, Van Wijngaerden E, De Waele J, Lademacher C, Engelhardt M, Kovanda L, Croos-Dabrera R, Fredericks C, Thompson GR. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. Clin Infect Dis. 2019 May 30;68(12):1981-1989. doi: 10.1093/cid/ciy827.

Reference Type DERIVED
PMID: 30289478 (View on PubMed)

McCormack PL. Isavuconazonium: first global approval. Drugs. 2015 May;75(7):817-22. doi: 10.1007/s40265-015-0398-6.

Reference Type DERIVED
PMID: 25902926 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://astellasclinicalstudyresults.com/study.aspx?ID=295

Link to results on the Astellas Clinical Study Results website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WSA-CS-008

Identifier Type: OTHER

Identifier Source: secondary_id

2006-003951-18

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

9766-CL-0105

Identifier Type: -

Identifier Source: org_study_id

NCT00444366

Identifier Type: -

Identifier Source: nct_alias